Zydus Healthcare appoints Swati Dalal MD

Zydus Lifesciences Ltd on Monday announced the appointment of Swati Dalal as an additional director and Managing Director of its wholly-owned arm Zydus Healthcare Ltd.

The board of Zydus Healthcare Ltd (ZHL) at its meeting held on June 16, 2025, approved the appointment of Swati Dalal as an additional director and the Managing Director of ZHL with effect from June 16, 2025, for five years, Zydus Lifesciences Ltd said in a regulatory filing.

Dalal, whose last role was Managing Director of Abbott India Ltd, has experience of over 30 years, the filing said.

She started her career with Wockhardt Nutrition and later joined erstwhile Boots. Through subsequent mergers with Knoll, Solvay and Abbott, she progressed in her career with various leadership roles across Abbott, including Commercial Director Sales & Marketing and Business Development & Commercial Excellence, among others.

She is a graduate in pharmacy from PKM Kundnani College of Pharmacy, Mumbai and a post-graduate degree in Management Studies from Jamnalal Bajaj Institute of Management Studies in Mumbai, it added.

Related Posts

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform